FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, L2
Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
January 2026 44th Annual Healthcare Conference Redefining Possibilities in Rare Disease
HERIZON-GEA-01 Phase 3 Results Favor Ziihera® as First-Line HER2-Targeted Therapy in Advanced Gastroesophageal Cancer
Financial Results, Press Release
Dr. Ted Love Appointed to Jazz Pharmaceuticals Board of Directors
Other Events
Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Shareholder votes
FY 2024
Q3
Q2
Q1
Amended Annual Report
FY 2023
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party